INSULIN-LIKE GROWTH-FACTORS AND THEIR BINDING-PROTEINS IN THE TERM AND PRETERM HUMAN FETUS AND NEONATE WITH NORMAL AND EXTREMES OF INTRAUTERINE GROWTH
INSULIN-LIKE GROWTH-FACTORS AND THEIR BINDING-PROTEINS IN THE TERM AND PRETERM HUMAN FETUS AND NEONATE WITH NORMAL AND EXTREMES OF INTRAUTERINE GROWTH
复制标题
DOI：
10.1210/jc.80.5.1548
复制
发表时间：
1995-05-01
影响因子：
5.8
通讯作者：
ROSENFELD, RG
中科院分区：
文献类型：
--
作者：
GIUDICE, LC;DEZEGHER, F;ROSENFELD, RG
胰岛素样生长因子（IGFs）、igf结合蛋白（igfbp）和胰岛素被认为在调节胎儿和新生儿生长中起重要作用。我们之前报道过，胎儿脐带血清（FCS）中igfbp的谱依赖于胎儿的生长/代谢状态。本研究的目的是检测生长正常的足月胎儿、宫内生长迟缓（IUGR）胎儿、大胎龄（LGA）胎儿的FCS中的IGF系统，以及正常体重早产儿（25-37周）和新生儿期从出生之日（第0天）到7天（第7天）的足月胎儿的FCS。期FCS Western ligand blotting （WLB）显示的igfbp分子质量分别为43和38千道尔顿（kDa; IGFBP-3）、34千道尔顿（IGFBP-2）、28千道尔顿（IGFBP-1和糖基化的IGFBP-4）和24千道尔顿（IGFBP-4）。在IUGR FCS中，WLB检测到的IGFBP-3减少了50%，这表明不是由于IUGR血清中存在IGFBP-3蛋白酶。在LGA FCS中，通过配体印迹密度分析，IGFBP-3水平升高了2倍。在正常FCS中，存在以下水平（+/- SE）： IGF-I, 76 +/- 16；Igf-ii, 401 +/- 38；igfbp - 3,700 +/- 112；IGFBP-1, 77 +/- 10 ng/mL；胰岛素3.8 +/- 1.6 mu U/mL。在IUGR FCS中，IGF-I、IGF-II和IGFBP-3显著降低，IGFBP-1比正常体重胎儿的FCS高7倍。在LGA FCS中，igf -1、胰岛素、IGFBP-3显著升高，IGFBP-1显著降低。在新生儿期，足月（38-40周）FCS第0天的IGF-I水平比早产儿（25-31周）高4倍。妊娠25-40周FCS IGF-II水平在第0天无显著变化。在出生后的前7天，早产儿的IGF-I水平没有变化，而足月新生儿的IGF-I水平在第1天急剧下降，在出生后的前3天保持较低水平，并在第一周结束时恢复到出生时的水平。相比之下，IGF-II和IGFBP-3水平在早产儿和足月新生儿出生后的第一周没有显著变化。不同的IGFBP和胰岛素样肽水平的胎儿正常与极端的宫内生长和变化的IGF- i水平在妊娠晚期和新生儿期提示IGF系统在人体的生长和发育的作用，胎儿和新生儿。
Insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and insulin are believed to be important in the regulation of fetal and neonatal growth. We previously reported that the profiles of IGFBPs in fetal cord serum (FCS) were dependent on the growth/metabolic status of the fetus. The goals of the current study were to examine the IGF system in FCS from term fetuses with normal growth, those with intrauterine growth retardation (IUGR), and those who were large for gestational age (LGA) and in FCS from normal weight preterm (25-37 weeks) and term fetuses in the neonatal period from the day of birth (day 0) until 7 days of age (day 7). Western ligand blotting (WLB) of term FCS revealed IGFBPs with mol wt of 43 and 38 kilodaltons (kDa; IGFBP-3), 34 kDa (IGFBP-2), 28 kDa (IGFBP-1 and glycosylated IGFBP-4), and 24 kDa (IGFBP-4). In IUGR FCS, there was a 50% decrease in IGFBP-3 detected by WLB, which was shown not to be due to an IGFBP-3 protease in IUGR sera. In LGA FCS, IGFBP-3 levels were elevated 2-fold by densitometric analysis of ligand blots. In normal term FCS, the following levels (+/- SE) were present: IGF-I, 76 +/- 16;IGF-II, 401 +/- 38;IGFBP-3, 700 +/- 112;IGFBP-1, 77 +/- 10 ng/mL; and insulin, 3.8 +/- 1.6 mu U/mL. In IUGR FCS, IGF-I, IGF-II, and IGFBP-3 were significantly reduced, and IGFBP-1 was 7-fold higher than in FCS from normal weight fetuses. In LGA FCS, IGF-I, insulin, and IGFBP-3 were significantly increased, whereas IGFBP-1 was significantly decreased. During the neonatal period, IGF-I levels on day 0 were 4-fold higher in FCS from term (38-40 weeks) compared to preterm (25-31 weeks) newborns. FCS IGF-II levels did not change significantly on day 0 between 25-40 weeks gestation. In the first 7 days of postnatal life, IGF-I levels were unchanged in preterm newborns, whereas in term neonates, IGF-I levels decreased precipitously on day 1, remained low during the first 3 days of life, and returned to birth levels by the end of the first week. In contrast, IGF-II and IGFBP-3 levels did not significantly change during the first week of life in preterm or term newborns. Different IGFBP and insulin-like peptide levels in fetuses with normal compared to extremes of intrauterine growth and changes in IGF-I levels in the third trimester and the neonatal period suggest roles for the IGF system in the somatic growth and development of the human fetus and neonate.